The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participan…

Alzheimer DiseaseAmyloidPlaque, Amyloid+1 more

~Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07787169

Phase 1

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, th…

Healthy VolunteersAlzheimer DiseaseAmyloid+1 more

~Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07787182

Phase 3

An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each part…

Alzheimer DiseaseDementiaPlaque, Amyloid

~Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07602582